{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:23Z","timestamp":1790173343576,"version":"4.1.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"17","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,7,31]]},"DOI":"10.2217\/fon-2017-0646","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T07:09:00Z","timestamp":1518160140000},"page":"1669-1678","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":71,"title":["FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer"],"prefix":"10.1080","volume":"14","author":[{"given":"Kathleen N","family":"Moore","sequence":"first","affiliation":[{"name":"Department of Obstetrics &amp; Gynecology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology, Leuven Cancer Institute, Leuven3000, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall D\u2019Hebron Institute of Oncology (VHIO), Barcelona08035, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, The European Institute of Oncology, Milan20141, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Gynaecology Unit, Royal Marsden Hospital, London, SW3 6JJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology &amp; Hematology, Princess Margaret Cancer Centre, TorontoM5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[{"name":"Department of Adult Medicine, Gustave Roussy Cancer Campus, Villejuif94800, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Malek","sequence":"additional","affiliation":[{"name":"Clinical Development, ImmunoGen, Inc., Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Birrer","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0084"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-07477-6.50028-7"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.5528\/wjtm.v3.i1.1"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.02.038"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-1-26"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014544121"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1408"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.09.050"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1312"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.014.10274"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.08.017"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.311"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9539-8"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/130.2.129"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020"},{"issue":"6","key":"e_1_3_4_20_1","first-page":"3567","article-title":"Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue","volume":"28","author":"Markert S","year":"2008","unstructured":"Markert S , LassmannS, GabrielBet al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res.28(6A), 3567\u20133572 (2008).","journal-title":"Anticancer Res."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3182774562"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S40947"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.10.002"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv250"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2596"},{"key":"e_1_3_4_27_1","article-title":"Merck and endocyte announce independent DSMB recommends vintafolide PROCEED Phase III trial be stopped for futility following interim analysis","author":"Levin J","year":"2014","unstructured":"Levin J . Merck and endocyte announce independent DSMB recommends vintafolide PROCEED Phase III trial be stopped for futility following interim analysis. FierceBiotech (2014). www.fiercebiotech.com\/biotech\/merck-and-endocyte-announce-independent-dsmb-recommends-vintafolide-proceed-phase-3-trial.","journal-title":"FierceBiotech"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201307628"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines4030014"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30030-4"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0519-6"},{"issue":"6","key":"e_1_3_4_32_1","first-page":"e254","article-title":"Antibody\u2013drug conjugates for cancer treatment","volume":"17","author":"Lambert JM","year":"2017","unstructured":"Lambert JM , BerkenblitA. Antibody\u2013drug conjugates for cancer treatment. Annu. Rev. Med.17(6), e254\u2013e262 (2017).","journal-title":"Annu. Rev. Med."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.11.002"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0645"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117523"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3973"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.11.002"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30736"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"e_1_3_4_43_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Mirvetuximab soravtansine (IMGN853), a folate alpha (FR-\u03b1)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian caner (EOC) patients (pts): activity and safety analyses in Phase I pooled expansion cohorts","volume":"35","author":"Moore KN","year":"2017","unstructured":"Moore KN , MatulonisUA, O\u2019MalleyDMet al. Mirvetuximab soravtansine (IMGN853), a folate alpha (FR-\u03b1)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian caner (EOC) patients (pts): activity and safety analyses in Phase I pooled expansion cohorts. J. Clin. Oncol.35(Suppl.), Abstract 5547 (2017).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.5.609"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/028418602320404998"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.130"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.10.036"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.120"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMR.S15558"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5921"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081315"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.08.331"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802707139"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8911"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:44:41Z","timestamp":1719110681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":52,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,7,31]]}},"alternative-id":["10.2217\/fon-2017-0646"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0646","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}